The FDA has also approved a new 10mg dose formulation of Nexium for delayed-release oral suspension for use in children one to 11 years old and the product will be available later this year.
Marta Illueca, Nexium brand medical director, AstraZeneca Pharmaceuticals US, said: “This dosing alternative of Nexium for oral suspension allows patients, such as children and the elderly, who are unable to swallow capsules or tablets to have an alternative treatment option for controlling their GERD.”